Seminal
The magazine and atlas of EU-funded researchA new publication from the web and AI team at Scott Charnley

Atlas / Germany

Marie Skłodowska-Curie Action · Running

ENDAMR Exploring Novel Drivers of Anti-Microbial Resistance

Coordinator
European Molecular Biology Laboratory, Germany
Runs
1 January 2025 to 31 December 2028
Status
Running
EU funding
€2.7m
Total cost
—
Partners
16 organisations in 9 countries
Type
Marie Skłodowska-Curie Action
Grant agreement
101168570

What the project is doing

In the project's own words, from its summary on CORDIS.

Antibiotic resistance (AMR) is a major public health issue, with 5 million deaths in 2019 linked to AMR worldwide. These numbers are comparable to the toll of the SARS-CoV-2 pandemic. Without new solutions, AMR is projected to soon become one of the leading causes of death in the EU. Addressing this challenge requires the development of new, effective antibiotics, but this alone is not sufficient due to the rapid evolution of bacteria.

Understanding the drivers and mechanisms of AMR is vital to delay or reverse resistance in both existing and new antibiotics, especially since no new broad-spectrum antibiotics have been developed since the 1990s and their development is a lengthy process with high attrition rates. The ENDAMR doctoral network aims to better equip researchers in Europe to understand and develop new strategies to tackle AMR. WP1 focuses on how AMR affects the fitness of pathogenic bacteria in the gut microbiome, aiming to identify microbiome characteristics that predispose to AMR infections and to explore microbiome-based interventions.

WP2 examines AMR acquisition via horizontal gene transfer, investigating evolutionary pathways, host genetics, environmental factors, dissemination, and AMR reservoirs. WP3 is dedicated to understanding the frequency, mechanisms, and clinical implications of antibiotic resistance, with a particular focus on the less studied aspects of heteroresistance and tolerance, and to developing diagnostic tools and predictive models.

WP4 explores the combination of antibiotics to enhance treatment outcomes and potentially prevent or reverse AMR, based on understanding the interplay of resistance mechanisms. ENDAMR will also prepare doctoral candidates for various career paths beyond academia, including teaching, science communication, and entrepreneurship. Candidates will gain transferable skills and learn from industry role models, equipping them to make significant contributions to solving the AMR crisis.

Topics

Who is involved

OrganisationCityCountryRole
European Molecular Biology LaboratoryHeidelbergGermanyCoordinator
Universitat BaselBaselSwitzerlandAssociatedpartner
Eberhard Karls Universitaet TuebingenTuebingenGermanyParticipant
Sonja NossWiesbadenGermanyAssociatedpartner
Transmitting Science S.L.PieraSpainAssociatedpartner
Hun-Ren Szegedi Biologiai KutatokozpontSzegedHungaryParticipant
HUN-REN Szegedi Biologiai KutatokozpontSzegedHungaryParticipant
Szegedi TudomanyegyetemSzegedHungaryAssociatedpartner
The Hebrew University of JerusalemJerusalemIsraelParticipant
Fondazione Human TechnopoleMilanoItalyParticipant
Universita HumanitasPieve EmanueleItalyAssociatedpartner
Universitetet I Tromsoe - Norges Arktiske UniversitetTromsoNorwayParticipant
Faculdade De Medicina Da Universidade De LisboaLisboaPortugalAssociatedpartner
Fundacao Gimm - Gulbenkian Institute for Molecular MedicineLisboaPortugalParticipant
Umea UniversitetUmeaSwedenParticipant
Uppsala UniversitetUppsalaSwedenParticipant

Source: CORDIS, European Commission. Data of 5 Nov 2026, reused under the Commission's reuse policy. View on CORDIS · Grant DOI